The predictive ability of PD-L1, TMB, and MSI/dMMR remains uncertain largely due to the lack of standardized assays for determining biomarker status.104 Variability of commercial PD-L1 assays stems from the use of different PD-1/PD-1 antibodies, scoring systems, stained cells, cut-offs for PD-L1, and tumor types. This evidence concerns the gene CD274 and neoplasm.